Myeloid derived suppressor cells are numerically, functionally and phenotypically different in patients with multiple myeloma.

Publication Type:
Journal Article
Citation:
Leukemia & lymphoma, 2014, 55 (12), pp. 2893 - 2900
Issue Date:
2014-12
Full metadata record
Files in This Item:
Filename Description Size
ThumbnailFavaloro etal 2014-Epub-AoP.pdfPublished Version1.07 MB
Adobe PDF
Myeloid derived suppressor cells (MDSCs) are a heterogeneous population of cells that have been implicated as inhibitors of lymphopoiesis in patients with malignancies. They have a consensus phenotype of CD33+/CD11b+/HLA-DRlo/- and can be further divided into CD15 + granulocytic (G-MDSC) and CD14 + monocytic (M-MDSC) subsets. We characterized MDSCs in patients with multiple myeloma (MM) and found a significant increase in G-MDSCs in the blood of patients with progressive MM. Flow-sorted MDSCs from patients with MM induced the generation of regulatory T cells (Treg). MDSCs from both patients with MM and aged-matched controls demonstrated a dose-dependent inhibition of lymphocyte proliferation in carboxyfluorescein succinimidyl ester (CFSE)-tracking experiments. Granulocyte colony stimulating factor (G-CSF) administered to induce stem cell mobilization caused an increase in the number of MDSCs in the peripheral blood of patients with MM and a concentration of these immune-suppressive cells in peripheral blood stem cell collections. MDSCs are likely to cause immune dysfunction in patients with MM.
Please use this identifier to cite or link to this item: